ERβ-Selective Estrogen Ligands for Tissue-Specific Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current estrogen replacement therapies have negative side effects due to non-selective estrogen receptor modulation, leading to proliferative effects on certain tissues and increased risks of diseases like breast and uterine cancer, necessitating the development of compounds that can selectively target estrogen receptors to mimic the beneficial effects of estrogen without these adverse effects.
Innovation Solution
Development of specific estrogen receptor ligands, particularly selective for the estrogen receptor β isoform, which can act as agonists, partial agonists, antagonists, or partial antagonists, to modulate estrogen activity and treat conditions such as depressive disorders, osteoporosis, and cancers without the proliferative effects associated with non-selective estrogen receptor modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective estrogen replacement therapy is used, then beneficial effects of estrogen are achieved, but proliferative effects on breast and uterine tissues occur
Solution Approach 1:
The patent segments the estrogen receptor into two distinct isoforms (ERα and ERβ) with different tissue distributions and functions. By developing selective ligands that target only ERβ, the invention separates the beneficial estrogenic effects (mediated by ERβ in bone, brain, and cardiovascular tissue) from the harmful proliferative effects (mediated by ERα in breast and uterine tissue), thereby resolving the contradiction between therapeutic benefit and harmful side effects
Solution Approach 2:
The patent applies local quality by creating ERβ-selective ligands that produce estrogenic effects specifically in tissues expressing ERβ (bone, brain, cardiovascular system) while avoiding activation of ERα in proliferative tissues. This localized action maintains beneficial effects in target tissues while eliminating harmful proliferative effects in breast and uterine tissues
2Reliability
If natural estrogen is used for treatment, then anti-depressant activity is achieved, but risk of proliferative effects increases
Solution Approach 1:
The patent segments estrogen receptor activity into ERα-mediated proliferative effects and ERβ-mediated anti-depressant and neuroprotective effects. By using ERβ-selective ligands, the invention isolates the anti-depressant activity (mediated through ERβ in the brain) from the harmful proliferative effects (mediated through ERα in breast and uterine tissue), thereby maintaining therapeutic benefit while reducing risk
Solution Approach 2:
The patent introduces ERβ-selective ligands as intermediary substances that mediate the anti-depressant effects of estrogen without directly activating ERα. These ligands act as selective intermediaries that transmit the beneficial neuroprotective and anti-depressant signals through ERβ while blocking the harmful proliferative signals that would require ERα activation
3Object-generated harmful factors
If selective ERβ ligands are developed, then proliferative effects are reduced, but compound complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters (substituents, functional groups, steric configurations) of the core indole scaffold to achieve ERβ selectivity. By adjusting these chemical parameters, the invention creates compounds that selectively activate ERβ over ERα, thereby reducing proliferative effects while managing structural complexity through rational design
Data Source
AI summary
The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification.